Publish in this journal
Journal Information
Vol. 72. Issue 6.
Pages 518-519 (June 2019)
Share
Share
Download PDF
More article options
Vol. 72. Issue 6.
Pages 518-519 (June 2019)
Letter to the Editor
DOI: 10.1016/j.rec.2018.11.018
Full text access
Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors
Estimación del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de la PCSK9
Visits
...
Alberto Corderoa,b,
Corresponding author
acorderofort@gmail.com

Corresponding author:
, Lorenzo Fácilac, Enrique Galved, José Ramón González Juanateyb,e
a Departamento de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
c Departamento de Cardiología, Hospital General Universitario de Valencia, Valencia, Spain
d Departamento de Cardiología, Hospital Vall d’Hebron, Barcelona, Spain
e Departamento de Cardiología, Complejo Hospital Universitario de Santiago, Santiago de Compostela, A Coruña, Spain
Related content
Rev Esp Cardiol. 2018;71:1010-710.1016/j.rec.2018.03.003
Alberto Zamora, Luís Masana, Marc Comas-Cufi, Núria Plana, Àlex Vila, Maria García-Gil, Lia Alves-Cabratosa, Roberto Elosua, Jaume Marrugat, Rafel Ramos
Rev Esp Cardiol. 2019;72:519-2010.1016/j.rec.2018.12.009
Alberto Zamora, Luis Masana, Nuria Plana, Rafel Ramos
This item has received
...
Visits
(Daily data update)
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
To the Editor,

We read with great interest the article by Zamora et al.,1 in which they estimated the number of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. We thought it particularly interesting that, although they found a relatively low percentage of patients with cardiovascular disease to be eligible for these drugs, this patient group had the highest absolute number of eligible patients. We consider these results to be highly relevant to clinical practice, as they show that 19.8% of patients with cardiovascular disease met the criteria to receive PCSK9 inhibitors based on a low-density-lipoprotein cholesterol (LDL-C) level > 100mg/dL despite maximal lipid-lowering therapy.

We estimated the percentage of patients that would be eligible for PCSK9 inhibitors based on LDL-C levels > 100mg/dL despite maximal lipid-lowering therapy in the 1281 patients with cardiovascular disease in the REPAR Study (Registro Paciente de Alto Rieso Cardiovascular; in English, the High-Cardiovascular-Risk Patient Registry). This registry previously demonstrated that treatment with high-dose statins was associated with improved LDL-C control,2 although this was only achieved in less than 40% of patients. In the group of patients with established cardiovascular disease (91% of whom had ischemic heart disease), 33.6% of patients were receiving high-dose statins and 5.4% were receiving high-dose statins plus ezetimibe. As can be seen in Figure 1, the percentage of patients with LDL-C > 100mg/dL despite taking high-dose statins with or without ezetimibe was 27.3% and 18.8%, respectively; this percentage was 44.8% and 24.6% in patients who were receiving medium-dose statins with or without ezetimibe, respectively.

Figure 1.

Percentage of patients with LDL-C values greater than or less than 100mg/dL according to the lipid-lowering therapy received. LDL-C, low-density-lipoprotein cholesterol.

(0.13MB).

Dyslipidemia remains one of the most poorly-controlled factors in patients with established cardiovascular disease.3,4 Treatment with high-dose statins has been demonstrated to be effective in controlling LDL-C and reducing the incidence of cardiovascular complications5; combined treatment with ezetimibe also improves LDL-C control and prognosis.5 However, a large percentage of patients do not meet LDL-C treatment target levels despite maximum-dose treatment.2–4 Poor control may also be attributed to additional factors such as low treatment adherence, an effect that cannot be excluded in our analysis. PCSK9 inhibitors are a new treatment option that has been demonstrated to be safe and effective for LDL-C control and that reduces the incidence of cardiovascular complications.6 The data from both the study by Zamora et al.1 and the REPAR Study provide evidence that there is a high percentage of patients with established cardiovascular disease who are eligible for PCSK9 inhibitors after optimization of lipid- lowering therapy and lifestyle factors.

Acknowledgements

The REPAR Study received an unconditional grant from Ferrer laboratories, Spain.

References
[1]
A. Zamora, L. Masana, M. Comas-Cufi, et al.
Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real.
Rev Esp Cardiol., 71 (2018), pp. 1010-1017
[2]
E. Galve, A. Cordero, A. Cequier, E. Ruiz, J.R. Gonzalez-Juanatey.
Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos.
Estudio REPAR. Rev Esp Cardiol., 69 (2016), pp. 931-938
[3]
A. Cordero, E. Galve, V. Bertomeu-Martínez, et al.
Tendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014.
Rev Esp Cardiol., 69 (2016), pp. 401-407
[4]
Z. Reiner, G. De Backer, Z. Fras, et al.
Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey.
Atherosclerosis., 246 (2016), pp. 243-250
[5]
L. Perez de Isla, P.L. Fernandez, L. Alvarez-Sala Walther, et al.
Comentarios a la guía ESC/EAS 2016 sobre el tratamiento de las dislipemias.
Rev Esp Cardiol., 70 (2017), pp. 72-77
[6]
M.S. Sabatine, R.P. Giugliano, A.C. Keech, et al.
Evolocumab and clinical outcomes in patients with cardiovascular disease.
N Engl J Med., 376 (2017), pp. 1713-1722
Copyright © 2018. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.